Department of Radiation Oncology, Institute of Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
J Nucl Med. 2010 Jun;51(6):866-74. doi: 10.2967/jnumed.109.069310. Epub 2010 May 19.
Accelerated tumor cell proliferation is an important mechanism adversely affecting therapeutic outcome in head and neck cancer. 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a PET tracer to noninvasively image tumor cell proliferation. The aims of this study were to monitor early tumor response based on repetitive (18)F-FLT PET/CT scans and to identify subvolumes with high proliferative activity eligible for dose escalation.
Ten patients with oropharyngeal tumors underwent an (18)F-FLT PET/CT scan before and twice during radiotherapy. The primary tumor and metastatic lymph nodes (gross tumor volume, or GTV) were delineated on CT (GTV(CT)) and after segmentation of the PET signal using the 50% isocontour of the maximum signal intensity or an adaptive threshold based on the signal-to-background ratio (GTV(SBR)). GTVs were calculated, and similarity between GTV(CT) and GTV(SBR) was assessed. Within GTV(SBR), the maximum and mean standardized uptake value (SUV(max) and SUV(mean), respectively) was calculated. Within GTV(CT), tumor subvolumes with high proliferative activity based on the 80% isocontour (GTV(80%)) were identified for radiotherapy planning with dose escalation.
The GTV(CT) decreased significantly in the fourth week but not in the initial phase of treatment. SUV(max) and SUV(mean) decreased significantly as early as 1 wk after therapy initiation and even further before the fourth week of treatment. For the primary tumor, the average (+/-SD) SUV(mean) of the GTV(SBR) was 4.7 +/- 1.6, 2.0 +/- 0.9, and 1.3 +/- 0.2 for the consecutive scans (P < 0.0001). The similarity between GTV(CT) and GTV(SBR) decreased during treatment, indicating an enlargement of GTV(SBR) outside GTV(CT) caused by the increasing difficulty of segmenting tracer uptake in the tumor from the background and by proliferative activity in the nearby tonsillar tissue. GTV(80%) was successfully identified in all primary tumors and metastatic lymph nodes, and dose escalation based on the GTV(80%) was demonstrated to be technically feasible.
(18)F-FLT is a promising PET tracer for imaging tumor cell proliferation in head and neck carcinomas. Signal changes in (18)F-FLT PET precede volumetric tumor response and are therefore suitable for early response assessment. Definition of tumor subvolumes with high proliferative activity and dose escalation to these regions are technically feasible.
基于重复的(18)F-FLT PET/CT 扫描监测早期肿瘤反应,并确定适合剂量递增的高增殖活性亚体积。
10 例口咽肿瘤患者在放疗前和放疗期间进行了(18)F-FLT PET/CT 扫描。在 CT 上勾画原发性肿瘤和转移性淋巴结(GTV(CT)),并使用最大信号强度的 50%等浓度线或基于信号与背景比的自适应阈值(GTV(SBR))对 PET 信号进行分割后进行勾画。计算 GTV,并评估 GTV(CT)与 GTV(SBR)之间的相似性。在 GTV(SBR)内,计算最大和平均标准化摄取值(SUV(max)和 SUV(mean))。在 GTV(CT)内,根据 80%等浓度线(GTV(80%))确定高增殖活性的肿瘤亚体积,用于剂量递增的放疗计划。
GTV(CT)在第四周明显缩小,但在治疗初期没有缩小。SUV(max)和 SUV(mean)在治疗开始后 1 周内显著下降,甚至在第四周治疗前进一步下降。对于原发性肿瘤,GTV(SBR)的平均(+/-SD)SUV(mean)分别为连续扫描的 4.7+/-1.6、2.0+/-0.9 和 1.3+/-0.2(P<0.0001)。治疗期间,GTV(CT)与 GTV(SBR)之间的相似性降低,表明由于肿瘤内示踪剂摄取与背景之间的分割难度增加以及附近扁桃体组织的增殖活性增加,GTV(SBR)在 GTV(CT)之外扩大。在所有原发性肿瘤和转移性淋巴结中均成功识别出 GTV(80%),并证明基于 GTV(80%)的剂量递增在技术上是可行的。
(18)F-FLT 是一种有前途的头颈部癌肿瘤细胞增殖 PET 示踪剂。(18)F-FLT PET 的信号变化先于体积肿瘤反应,因此适合早期反应评估。定义高增殖活性的肿瘤亚体积并对这些区域进行剂量递增在技术上是可行的。